Американское общество гирудотерапии

Identification and characterization of novel anticoagulant peptide with thrombolytic effect and nutrient oligopeptides from Whitmania pigra

Peptidomics study published in Amino Acids (2016)

Последнее обновление: June 18, 2026Рецензент: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportГеномика и протеомикаФармакология секрета слюнных желёзRen Y et al. · Amino acids, 2016

Abstract

Natural and nutrient substances for cardiovascular disease are promising and capture researchers' minds. Two kinds of novel bioactive peptides (high Fischer's ratio oligopeptides and anticoagulant peptides) were obtained from Whitmania pigra protein via enzymatic hydrolysis. An oligopeptide (MW<874.0 Da) named as HF2 was obtained via chromatography purification procedures with a high Fischer's ratio of 31.92 ± 1.36 and low phenylalanine + tyrosine content of 0.98 ± 0.04 %. Another peptide (WA3-1), prepared by alcalase AF 2.4 L-catalyzed hydrolysis and then purified by DEAE Sepharose FF, gel Sephadex G-15 chromatography, exhibited high anticoagulant activity with prolonging significantly plasma clotting time on activated partial thromboplastin time, prothrombin time, thrombin time (p < 0.01) and powerful thrombolytic activity. Amino acid composition and MALDI-TOF/TOF MS analysis showed that WA3-1 contained 11 amino acids (MW: 1422.0 Da) with the sequence as NH2-His-Asp-Phe-Leu-Asn-Asn-Lys-Leu-Glu-Tyr-Glu-COOH. Abundant negatively charged amino acids in C-terminal, as well as the special residue Lys contribute to its anticoagulant capacity. This research provided a novel natural candidate for the manufacture of nutrient oligopeptides with high branched chain amino acid, and anticoagulant thrombolytic agent in pharmaceutical industry with helping prevent from thrombosis and related cardiovascular diseases.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAmino Acid SequenceAmino Acids, Branched-ChainAnimalsAnticoagulantsBlood CoagulationHumansLeechesOligopeptidesThrombolytic Therapy

Резюме

Discovers a novel anticoagulant peptide with thrombolytic activity and nutrient oligopeptides rich in branched-chain amino acids in Whitmania pigra hydrolysates.

Почему это важно для гирудотерапии

This study isolated and characterized two novel bioactive peptides from Whitmania pigra protein via enzymatic hydrolysis and chromatographic purification: a high Fischer's ratio oligopeptide (HF2, MW < 874.0 Da, Fischer's ratio 31.92 ± 1.36) and an anticoagulant peptide (WA3-1, MW 1422.0 Da, sequence NH2-His-Asp-Phe-Leu-Asn-Asn-Lys-Leu-Glu-Tyr-Glu-COOH). WA3-1 significantly prolonged activated partial thromboplastin time, prothrombin time, and thrombin time (p < 0.01) and exhibited thrombolytic activity, with negatively charged C-terminal amino acids and a Lys residue contributing to its anticoagulant capacity. This is relevant to ASH's domain as it characterizes novel anticoagulant and thrombolytic peptides from a leech species (per MeSH classification), identifying potential bioactive components of medicinal interest. However, all activity data are from in vitro plasma clotting assays and compositional analysis; no in vivo efficacy, pharmacokinetic, or safety data are presented.

Цитирование

Identification and characterization of novel anticoagulant peptide with thrombolytic effect and nutrient oligopeptides from Whitmania pigra.

Ren Y et al. · Amino acids, 2016

Связанный клинический контекст

Добавлено в библиотеку ASH: May 27, 2026 · Последнее обновление сайта: June 18, 2026

Этот сайт предоставляет образовательную информацию и не является медицинской консультацией, диагнозом или рекомендацией по лечению. Гирудотерапия сопряжена с клинически значимыми рисками и должна проводиться только квалифицированными клиницистами в рамках институционально утверждённых протоколов. Разрешение FDA 510(k) для медицинских пиявок ограничено определёнными показаниями; обсуждения исследовательского и нелицензионного применения отмечены соответствующим образом. Для индивидуальных медицинских рекомендаций обратитесь к квалифицированному медицинскому специалисту.